NCT06314828View on ClinicalTrials.gov

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2027

Conditions
B-cell Non-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

RJMty19 (CD19-CAR-DNT cells)

Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

collaborator

Southern Medical University, China

OTHER

collaborator

Beijing GoBroad Hospital

OTHER

lead

Guangdong Ruishun Biotech Co., Ltd

INDUSTRY

NCT06314828 - A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL | Biotech Hunter | Biotech Hunter